Rutgers Cancer Institute of New Jersey researcher and surgical oncology Darren R. Carpizo, MD, PhD, has been awarded a $1,839,863 grant (R01-CA200800) from the National Cancer Institute to build upon research from his laboratory examining a drug compound that restores tumor suppressor function in the most commonly mutated gene in human cancer - the p53 gene. The aim is to provide the foundation for the development of a new class of anti-cancer drugs that will target p53, resulting in broad activity against all cancer types.
BioMotiv, a drug development accelerator associated with The Harrington Project, and Rutgers, the State University of New Jersey, are announcing the formation of a new biotechnology startup, Z53 Therapeutics. Z53 Therapeutics aims to develop novel anti-cancer drugs that target tumors with p53 mutations.
Dr. Carpizo's research is focused on developing a new class of therapeutics that will target one of the most common protein mutations in human cancer.